Johnson & Johnson (NYSE:JNJ) Stock Holdings Cut by Gilbert & Cook Inc.

Gilbert & Cook Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 8,762 shares of the company’s stock after selling 299 shares during the period. Gilbert & Cook Inc.’s holdings in Johnson & Johnson were worth $1,267,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. AMF Tjanstepension AB boosted its stake in shares of Johnson & Johnson by 14.2% during the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after acquiring an additional 52,997 shares in the last quarter. Czech National Bank boosted its stake in shares of Johnson & Johnson by 6.9% during the 3rd quarter. Czech National Bank now owns 490,381 shares of the company’s stock worth $79,471,000 after acquiring an additional 31,766 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Johnson & Johnson by 40.4% during the 3rd quarter. GAMMA Investing LLC now owns 35,924 shares of the company’s stock worth $5,822,000 after acquiring an additional 10,332 shares in the last quarter. Davis Investment Partners LLC boosted its stake in shares of Johnson & Johnson by 2.4% during the 3rd quarter. Davis Investment Partners LLC now owns 3,118 shares of the company’s stock worth $503,000 after acquiring an additional 72 shares in the last quarter. Finally, Alpha Financial Partners LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth $209,000. 69.55% of the stock is owned by institutional investors.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Citigroup reduced their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Stifel Nicolaus reduced their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Bank of America reduced their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Raymond James reduced their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Finally, Wells Fargo & Company reduced their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $170.44.

Johnson & Johnson Price Performance

NYSE JNJ opened at $152.09 on Monday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The stock’s 50-day moving average is $147.61 and its two-hundred day moving average is $156.13. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market cap of $366.17 billion, a P/E ratio of 22.87, a price-to-earnings-growth ratio of 2.43 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same period last year, the company earned $2.29 earnings per share. On average, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.26%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.